Of six candidate strains of Shigella prepared in Brain Heart Infusion broth as freeze-dried vaccine, low survival rates were obtained with two of the most promising strains. Survival rates with these two strains were increased to acceptable levels when the organisms were suspended in a medium consisting of 8.2% sucrose, 0.01 M phosphate, 0.07% monosodium glutamate, and 2.5% human serum albumin. Alteration of the freezing temperature did not improve the recovery rates significantly.
Of six candidate strains of Shigella prepared in Brain Heart Infusion broth as freeze-dried vaccine, low survival rates were obtained with two of the most promising strains. Survival rates with these two strains were increased to acceptable levels when the organisms were suspended in a medium consisting of 8.2% sucrose, 0.01 M phosphate, 0.07% monosodium glutamate, and 2.5% human serum albumin. Alteration of the freezing temperature did not improve the recovery rates significantly.
Formal et al. (3) described the biological properties of freeze-dried live Shigella vaccines prepared with two S. flexneri 2a strains of reduced virulence, and demonstrated that these freeze-dried preparations remained viable and retained their biological activity for periods as long as 2 years at 4 C.
Since the above-mentioned report was published, other strains of Shigella have been investigated as potential candidates for freezedried vaccine. Although these strains were grown and processed in the same manner as the two strains described by Formal, the recovery rates, as measured by the per cent of viable organisms surviving the freeze-drying procedure, varied considerably among the different strains.
To improve the recovery rates of the strains which did not survive the freeze-drying process to a reasonable degree (arbitrarily set at greater than 50% recovery), the effect of factors such as the suspending medium (4) and the freezing temperature (6) was investigated. It was considered important to improve the viability of the dried product in order to reduce the dose volume required to provide the desired number of viable organisms, and to ensure that the surviving organism would be representative of the characteristics of the organisms in the original fluid harvests.
MATERIALS AND METHODS
Bacterial cultures. All bacterial cultures employed in this study were maintained in the freeze-dried state. The designation of the strains employed and their characteristics are summarized in Table 1 . Shigella strains defined as "avirulent" were incapable of (i) penetrating HeLa cells, (ii) causing keratoconjunctivitis, (iii) causing fatal enteric infection in starved, opiated guinea pigs, and (iv) producing evidence of clinical disease when fed to monkeys (5).
The Escherichia coli-S. flexneri hybrid strain M22-18X16 was prepared by mating Hfr E. coli strain W1895 with virulent S. flexneri 2a strain M22-18 and selecting for xylose-positive recombinants (2) . The E. coli-S. flexneri hybrid strain 24570X130 was prepared in a similar manner by the mating of Hfr E. coli strain W1895 with avirulent S. flexneri strain 24650.
Preparation of vaccines. Agar-grown bacterial harvests were obtained and were freeze-dried according to the method described by Formal and co-workers (3).
Bacterial titrations. The number of viable organisms in the fluid and dried products was determined by spreading 0.1 ml of appropriate dilutions (in physiological saline) of the products onto the surface of Meat Extract Agar (MEA; Difco) plates. The MEA plates were then incubated at 36 C for 18 hr. Colonies were counted, and the per cent recovery after freezedrying was determined by comparing the number of viable organisms in the dried product with the number in the fluid harvest.
RESULTS
Recovery rates with the various Shigella strains.
Following the method described by Formal and co-workers (3), the strains of Shigella, grown on Brain Heart Infusion (BHI) agar (Difco) and harvested in Brain Heart Infusion (BHI) broth (Difco), were prepared as potential freeze-dried vaccines. The results of the plate counts on the fluid and dried products are shown in Table 2 . The recovery rates with the 2381-0, 2457-0, and 3-5-0 strains were 50% or greater and were considered satisfactory, but the rates of recovery with the 9774, M22-18X16, and 24570X130 strains were considered to be below acceptable levels. The two strains 9774 and 24570X130 appeared to have the greatest potential as vaccine strains and were therefore investigated further.
Effect ofharvesting medium and temperature of The harvests were then distributed in 10-ml volumes into 30-ml serum vials, and several bottles of each suspension were placed overnight at each of several different temperatures (-20, -42, and -60C) for freezing. Before the start of the drying cycle, the products frozen at temperatures other than -42 C (the temperature of the freeze-dryer shelves) were placed on the freeze-dryer shelves and were allowed to equilibrate for 1.5 hr. For these experiments, the drying cycle was altered from that of the vaccines prepared previously. The total drying time was 47 to 49 hr, including an average of 10 hr terminal drying at 8 to 14 C, as measured by an internal thermocouple situated in the product at the bottom of the bottle. Freezing of the bacterial suspensions at -42 or -60 C appeared to be somewhat more effective in preserving viability than freezing at -20 C, particularly with the 24570X130 strain suspended in BHI broth. However, the harvesting medium exerted a significant effect on recovery rates (Table 3 ). The recovery rates for the two strains of Shigella were consistently greater and attained acceptable levels when the organisms were harvested in SPG and HSA rather than in BHI broth. DISCussioN In a discussion on the preservation of living cells by freeze-drying, Greaves (4) stated that the most important single factor influencing survival rates after freeze-drying is the drying medium itself. Three of the six strains of Shigella examined in this study were able to survive the freezing and freeze-drying procedures to an acceptable degree when suspended in BHI broth. However, survival rates with two of the Shigella strains that were sensitive to the freeze-drying procedure were favorably affected when the organisms were suspended in SPG and HSA. Alteration of the freezing temperature, at least within the range that is available at this laboratory for practical use, did not improve the recovery rates significantly.
Preservation of these as well as other microorganisms by freeze-drying procedures provides a useful and convenient means of stabilizing cultures for long-term storage. The greater the survival rate, the more likely it is that the population in the dried product will approximate the characteristics of that in the original fluid preparation. In the case of live vaccines, the preparation of freeze-dried products has the additional advantage of holding the vaccines in a stable form during the extensive testing period required before they are used.
